UNICREDIT BANK/CALL/NOVO-NORDISK B/1100/0.1/18.12.24 | Market Closed - BOERSE MUENCHEN 03:45:53 2024-07-16 pm EDT | ||
| 0.61 EUR | -1.61% |
|
| Current month | -24.69% | ||
| 1 month | -26.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.61 | -1.61% |
| 24-07-15 | 0.62 | -3.13% |
| 24-07-12 | 0.64 | +10.34% |
| 24-07-11 | 0.58 | -13.43% |
| 24-07-10 | 0.67 | +6.35% |
Real-time BOERSE MUENCHEN
Last update July 16, 2024 at 03:45 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HC9ABD |
| ISIN | DE000HC9ABD1 |
| Date issued | 2023-09-18 |
| Strike | 1,100 kr |
| Maturity | 2024-12-18 (155 Days) |
| Parity | 10 : 1 |
| Emission price | 0.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.94 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.04 € |
| Spread % | 6.45% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
970
DKK
Average target price
957.1
DKK
Spread / Average Target
-1.33%
- Stock Market
- Warrants
- Warrant
